Name: Recombinant Human DR5 Protein (His Tag)
Brand: Beta LifeScience
SKU: BLPSN-1656
Availability: InStock

Catalog No.: BLPSN-1656

Product Overview

Tag	His
Host Species	Human
Accession	NP_003833.3
Synonym	CD262, DR5, KILLER, KILLER/DR5, TRAIL-R2, TRAILR2, TRICK2, TRICK2A, TRICK2B, TRICKB, ZTNFR9
Background	Tumor necrosis factor receptor superfamily, member 1b, official symbol TNFRSF1B, also known as Death receptor 5, CD262, TNF-related apoptosis-inducing ligand receptor 2 (TRAIL R2), is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF1/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. TRAIL R2/CD262/TNFRSF1B was purified independently as the only receptor for TRAIL detectable on the surface of two different human cell lines that undergo apoptosis upon stimulation with TRAIL. TRAIL R2/CD262/TNFRSF1B contains two extracellular cysteine-rich repeats, typical for TNF receptor (TNFR) family members, and a cytoplasmic death domain. TRAIL R2/CD262/TNFRSF1B mediates apoptosis via the intracellular adaptor molecule FADD/MORT1. TRAIL receptors can signal both death and gene transcription, functions reminiscent of those of TNFR1 and TRAMP, two other members of the death receptor family. Defects in TRAIL R2/CD262/TNFRSF1B may be a cause of head and neck squamous cell carcinomas (HNSCC) also known as squamous cell carcinoma of the head and neck.Immune CheckpointImmunotherapyCancer ImmunotherapyTargeted Therapy
Description	A DNA sequence encoding the human TNFRSF10B (NP_003833.3) extracellular domain (Met 1-Glu 182) was expressed, fused with a His tag at the C-terminus.
Source	HEK293
Predicted N Terminal	Ile 56
AA Sequence	Met 1-Glu 182
Molecular Weight	The recombinant human TNFRSF10B consists of 138 a.a. and has a predicted molecular mass of 15.8 kDa. As a result of glycosylation, the apparent molecular mass of rhTNFRSF10B is approxiamtely 20-22 kDa in SDS-PAGE under reducing conditions.
Purity	>95% as determined by SDS-PAGE
Endotoxin	< 1.0 EU per μg of the protein as determined by the LAL method
Bioactivity	1. Measured by its binding ability in a functional ELISA. Immobilized human TNFRSF10B at 10 ug/ml (100 ul/well) can bind biotinylated TNFSF10 with a linear range of 0.625-20 ng/ml.2. Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L-929 mouse fibroblast cells treated with TRAIL. The ED50 for this effect is typically 5-25 ng/mL in the presence of 10 ng/mL Recombinant Human TRAIL/TNFSF10.
Formulation	Lyophilized from sterile PBS, pH 7.4.
Stability	The recombinant proteins are stable for up to 1 year from date of receipt at -70°C.
Usage	For Research Use Only
Storage	Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.